MaRS Innovation specializes in extreme early-stage seed investing for companies and technology emerging from our 15 members.
Click on link to read an article by Drs. Rafi Hofstein and Werner Lanthaler published in December 2017 in the online publication Global University Venturing: http://bit.ly/2Ba9vH2
Toronto, Nov. 28, 2017 (GLOBE NEWSWIRE) — Fibrocor Therapeutics (Fibrocor) announced today that Mark Steedman has been appointed as its first president and CEO, and will serve as a member of Fibrocor’s board of directors.
TORONTO, November 1, 2017 – Encycle Therapeutics (“Encycle”), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called “nacellins,” today announced a …